TRANSVAC2: Funding for European vaccine research infrastructure

The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.

Vaccines are one of the most successful and cost-effective public health tools for disease prevention. Their development though is time-consuming and complex, requiring a combination of specialised skills and technical capacities not readily available at a single organisation.  In order to facilitate access to these skills and capacities and to promote collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines - the European Commission (EC), recently committed significant funding to TRANSVAC2.

Dr Odile Leroy, Executive Director of the European Vaccine Initiative (EVI) and coordinator of TRANSVAC2, comments: “The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges”.

Please read the press release (English or German) for more detailed information.